Birinapant (TL32711) is a bivalent Smac mimetic and potent XIAP and cIAP1 antagonist that promotes cIAP degradation, caspase-8 activation, and tumor cell death by disrupting TNF-driven NF-κB signaling, making it a promising candidate for targeted cancer therapy.
Usually ships within 24 hours.